ClinicalTrials.gg

Leukemia, Myeloid clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 136 studies for Leukemia, Myeloid across more than 10 countries. 23 are recruiting or about to start. 36 of them are mainly about Leukemia, Myeloid (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03. Counting its 16 narrower conditions too, such as Leukemia, Myeloid, Acute: 4,759 studies, 961 open.

Status

Completed
64
Terminated
24
Recruiting
19
Status unknown
16
Active, not recruiting
6
Not yet recruiting
4

Phase

Phase 1
54
Phase 2
53
Phase 3
15
Early Phase 1
5

Where

United States
85
France
21
Germany
17
Canada
16
China
15
Spain
14

Who develops what

Add Leukemia, Myeloid to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 0 with this as their studies’ main aim; 1 with a live phase 3 study; 0 primary completions in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
fludarabineRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07157514 · Actinium Pharmaceuticals · Phase 3 · live · background · “Fludarabine” · registered Aug 2025
Beijing Biotech18% of its industry studies11 study
CyclophosphamideRecent, limited
Evidence
  • NCT07157514 · Actinium Pharmaceuticals · Phase 3 · live · background · “Cyclophosphamide” · registered Aug 2025
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed11 study
imatinibEarlier only
Evidence
  • NCT02130557 · Pfizer · Phase 3 · comparator · “Imatinib” · registered May 2014
  • NCT01650805 · Takeda · Phase 3 · comparator · “imatinib (Gleevec/ Glivec)” · registered Jul 2012
  • NCT01511289 · Il-Yang Pharm. Co., Ltd. · Phase 3 · comparator · “Imatinib” · registered Jan 2012
  • NCT01503502 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “imatinib” · registered Jan 2012
  • NCT00114959 · Teva Pharmaceutical Industries, Ltd. · Phase 2 · background · “Imatinib Mesylate” · registered Jun 2005
Novartis76% of its industry studiesUS: off-patent, 8 generics marketedEU: off-patent, 2 generics authorized00 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Leukemia, Myeloid studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Antimetabolites 3 open · Alkylating agents 1 open

Coming up

10studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10

Who these studies take

Of the 19 Leukemia, Myeloid studies recruiting now, 10 (53%) set no upper age limit and 7 (37%) stop at 75 or younger. 5 (26%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 19
AgeWomenMen
104 (21%)4 (21%)
1818 (95%)18 (95%)
3018 (95%)18 (95%)
4017 (89%)17 (89%)
5018 (95%)18 (95%)
6518 (95%)18 (95%)
7515 (79%)15 (79%)
8511 (58%)11 (58%)

Across all 136 studies, recruiting or not: 29% stop at 75 or younger and 15% at 65; 22% take children; 1% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Myeloid studies take

Of 24 phase 1 interventional studies under Leukemia, Myeloid, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 148 mo30–74 · 24 studies——
Phase 248 mo36–72 · 18 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 136. Browse all 136 → or search them.